Barclays Takes Neutral Stance on Gilead Sciences (GILD) Despite Strategic Refocus

Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 13 Best NASDAQ Dividend Stocks to Buy Now. Barclays Takes Neutral Stance on Gilead Sciences (GILD) Despite Strategic Refocus On February 20, Barclays began coverage of Gilead Sciences, Inc. (NASDAQ:GILD) with an Equal Weight rating. The firm set a $155 price target on the stock. The firm said the company is returning its focus to what it has historically done well, developing treatments for infectious diseases. Still, Barclays believes the stock a ...